The following is the summary of “A Pilot Study on Human Circulating System Indicated That Regenerating Islet-Derived Protein 3 Gamma (REG3A) is a Potential Prognostic Biomarker for Sepsis” published in the March 2023 issue of Cardiovascular Disease by Ding, et al.

To reduce the likelihood that a patient would get severely injured or die as a result of sepsis, it is imperative that biomarkers for the disease be developed that can be recognized rapidly and reliably. In this work, researchers compared patients who had sepsis to healthy individuals who served as controls to determine the levels of blood protein expression of regenerating islet-derived protein 3 gamma (REG3A). 

In patients diagnosed with sepsis, we found that the levels of serum REG3A protein were much greater than in healthy patients. In addition, investigators discovered that the expression level of serum REG3A protein had a significant correlation with the Sequential Organ Failure Assessment score, the Acute Physiology and Chronic Health Evaluation II score, and the levels of C-reactive protein in patients who were suffering from sepsis. It was also shown that the blood REG3A protein expression level had a strong diagnostic value for distinguishing between people with sepsis and healthy controls. 

This was demonstrated by the fact that this distinction could be made. Furthermore, the level of blood REG3A protein expression was found to have a good predictive value for predicting the 28-day survival rate of individuals suffering from sepsis. In conclusion, this was discovered. The results of this study indicated that serum REG3A might be a candidate for use as a biomarker for septic shock.